COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA
Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Subcutaneously and Orally Administered Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral COVID-19 in Normal Healthy Volunteers
Sponsor: ImmunityBio, Inc.
Terminated
The study was terminated early due to low enrollment.
Other terminated trials from ImmunityBio, Inc.
- Non Small Cell Lung Cancer · Oct 2025
- COVID-19 · Phase PHASE1/PHASE2 · Mar 2024
- Triple Negative Breast Cancer · Phase PHASE1/PHASE2 · Jan 2024
- COVID-19 · Phase PHASE2/PHASE3 · Jul 2023
- Advanced Triple Negative Breast Cancer · Phase PHASE1/PHASE2 · Dec 2022
More terminations from ImmunityBio, Inc.
A PHASE1 clinical study on Covid19, this trial is terminated or withdrawn. The trial is conducted by ImmunityBio, Inc. and has accumulated 8 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Nov 2024 — Present [monthly]
Terminated PHASE1
Status: Unknown → Terminated
-
Sep 2024 — Nov 2024 [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Sep 2021 — Feb 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Feb 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ImmunityBio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .